Palivizumab antibody | AbD23967_hIgG1
A microtiter plate was coated over night with various antigens at a concentration of 5 μg/ml. After washing and blocking with PBST+5% BSA, detection was performed using HRP conjugated human anti palivizumab (clone AbD23967_hIgG1) at a concentration of 2 μg/ml in HISPEC diluent (BUF049A) and QuantaBlu fluorogenic peroxidase substrate.
A microtiter plate was coated over night with palivizumab, human IgG1/kappa or human IgG1/lambda at a concentration of 5 μg/ml. After washing and blocking with PBST+5% BSA, detection was performed using increasing concentrations of HRP conjugated human anti palivizumab (clone AbD23967_hIgG1) in HISPEC diluent (BUF049A) and QuantaBlu fluorogenic peroxidase substrate. Data for binding to palivizumab is presented as the mean of three measurements.
A microtiter plate was coated over night with human anti palivizumab (clone AbD23967) at a concentration of 1 μg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of palivizumab. Detection was performed using HRP-conjugated human anti palivizumab (clone AbD23967_hIgG1) at a concentration of 2 μg/ml in HISPEC assay diluent (BUF049A) and QuantaBlu fluorogenic peroxidase substrate. Data is presented as the mean of three measurements.
A microtiter plate was coated over night with human anti palivizumab (clone AbD23967_hIgG1) at a concentration of 0.5 μg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of palivizumab. Detection was performed using HRP-conjugated human anti palivizumab (clone AbD23967_hIgG1) at a concentration of 2 μg/ml in HISPEC assay diluent (BUF049A) and QuantaBlu fluorogenic peroxidase substrate. Data is presented as the mean of three measurements.
A microtiter plate was coated over night with palivizumab at concentrations between 0.5 and 1.5 μg/ml. After washing and blocking with PBST+5% BSA, PBST with 10% human serum was added spiked with increasing concentrations of human anti palivizumab (clone AbD23967_hIgG1). Detection was performed using HRP conjugated palivizumab at a concentration of 2 μg/ml in HISPEC assay diluent (BUF049A) and QuantaBlu fluorogenic peroxidase substrate. Data is presented as the mean of three measurements. HRP-conjugation of the antibody used in this assay was performed using a LYNX Rapid HRP Antibody Conjugation Kit.
Human anti Palivizumab:HRP
- Product Type
- Monoclonal Antibody
- Clone
- AbD23967_hIgG1
- Isotype
- IgG1
- Specificity
- Palivizumab
Antibody Quality and Performance Guarantee
| Human anti Palivizumab, clone AbD23967_hIgG1, is a paratope specific, high affinity, anti-idiotypic antibody that specifically recognizes the monoclonal antibody drug palivizumab and inhibits it binding to its target. The antibody can be used to measure the levels of palivizumab and biosimilar products in bioanalytical assays. Clone AbD23967_hIgG1 is a fully human recombinant monoclonal antibody with IgG1 isotype and is suitable as a reference standard in an anti-drug antibody (ADA) assay. Additionally the antibody can be used to develop a pharmacokinetic (PK) bridging assay to measure free drug. This antibody is recommended as the detection antibody and is available unlabeled or directly conjugated to HRP. Use in a pair with capture antibody clone AbD23967 (HCA261) in monovalent Fab format. Palivizumab (Synagis®) is a humanized mouse monoclonal antibody (IgG1/kappa) specific to an epitope of the F protein of respiratory syncytial virus (RSV). It binds the antigenic site A, a highly conserved region on the RSV F protein between amino acids 258 and 275. RSV is known to cause infections of the lower respiratory tract in a clear seasonal pattern during the winter months. Administration of the drug is recommended for premature infants (under 35 weeks gestation), infants with certain congenital heart defects (CHD) or bronchopulmonary dysplasia (BPD) throughout the duration of the RSV season. It is approved by the FDA and EMA as a treatment for respiratory tract infection caused by RSV. View a summary of all anti-palivizumab antibodies |
|
- Product Form
- Human IgG1 antibody selected from the HuCAL phage display library and expressed in a human cell line. Conjugated to horseradish peroxidase (HRP) - liquid.
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A
- Source
- HKB-11
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- 0.01% Thiomersal
- Immunogen
- Palivizumab
- Affinity
- The intrinsic affinity of the monovalent form of this antibody is KD=1.5 nM as measured by real time, label-free molecular interaction analysis on immobilized Palivizumab.
- Approx. Protein Concentrations
- IgG concentration 0.1 mg/ml
- Regulatory
- For research purposes only
- Guarantee
- 12 months from date of despatch
- Acknowledgements
- This product and/or its use is covered by claims of U.S. patents, and/or pending U.S. and non-U.S. patent applications owned by or under license to Bio-Rad Laboratories, Inc. See bio-rad.com/en-us/trademarks for details.
Synagis is a trademark of the AstraZeneca group of companies. - Licensed Use
- For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
This product is shipped frozen.
When ready to use, thaw and aliquot the sample as needed. Store aliquots at -70°C, if available, otherwise store at -20°C. It is not recommended to keep aliquots at 4°C for more than one week.
When ready to use, thaw and aliquot the sample as needed. Store aliquots at -70°C, if available, otherwise store at -20°C. It is not recommended to keep aliquots at 4°C for more than one week.
This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| ELISA |  |
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
- Technical Advice
- Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual.
- ELISA
- This product may be used as a detection reagent in a sandwich ELISA together with HCA261 as the capture reagent.
Protocol: PK bridging ELISA to measure free drug.
| Description | Product Code | Applications | Pack Size | List Price | Your Price | Quantity | |
|---|---|---|---|---|---|---|---|
| Hispec Assay Diluent | BUF049A | E IY | 50 ml | Log in | |||
| List Price | Your Price | ||||||
| Log in | |||||||
| Description | Hispec Assay Diluent | ||||||
| Human anti Palivizumab | HCA261 | E | 0.1 mg |
|
Log in | ||
| List Price | Your Price | ||||||
|
|
Log in | ||||||
| Description | Human anti Palivizumab | ||||||
| Human anti Palivizumab | HCA262 | E | 0.1 mg |
|
Log in | ||
| List Price | Your Price | ||||||
|
|
Log in | ||||||
| Description | Human anti Palivizumab | ||||||
References for Palivizumab antibody
-
Kashiwagi, N. et al. (2017) Method for measuring anti-drug antibody
US Patent Application US20170315118A1
- Synonyms
- SYNAGIS®
HCA262P
151585
If you cannot find the batch/lot you are looking for please contact our technical support team for assistance.
View more products with PALIVIZUMAB specificity
Please Note: All Products are "FOR RESEARCH PURPOSES ONLY"
Always be the first to know.
When we launch new products and resources to help you achieve more in the lab.
Yes, sign me up